Vaxcyte Inc (PCVX)
88.54
+0.15
(+0.17%)
USD |
NASDAQ |
Nov 22, 16:00
89.00
+0.46
(+0.52%)
After-Hours: 20:00
Vaxcyte Net Income (Quarterly): -103.12M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -103.12M |
| June 30, 2024 | -128.70M |
| March 31, 2024 | -95.02M |
| December 31, 2023 | -180.80M |
| September 30, 2023 | -92.66M |
| June 30, 2023 | -68.34M |
| March 31, 2023 | -60.46M |
| December 31, 2022 | -78.05M |
| September 30, 2022 | -57.92M |
| June 30, 2022 | -48.53M |
| March 31, 2022 | -38.99M |
| December 31, 2021 | -28.56M |
| Date | Value |
|---|---|
| September 30, 2021 | -26.62M |
| June 30, 2021 | -23.68M |
| March 31, 2021 | -21.22M |
| December 31, 2020 | -20.74M |
| September 30, 2020 | -21.02M |
| June 30, 2020 | -20.32M |
| March 31, 2020 | -27.14M |
| December 31, 2019 | -14.62M |
| September 30, 2019 | -11.32M |
| June 30, 2019 | -10.66M |
| March 31, 2019 | -13.67M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-180.80M
Minimum
Dec 2023
-14.62M
Maximum
Dec 2019
-57.83M
Average
-43.76M
Median
Net Income (Quarterly) Benchmarks
| Pfizer Inc | 4.465B |
| Merck & Co Inc | 3.157B |
| Embecta Corp | 14.70M |
| Arrowhead Pharmaceuticals Inc | -170.79M |
| Dyne Therapeutics Inc | -97.12M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 139.63M |
| EPS Diluted (Quarterly) | -0.83 |
| Enterprise Value | 8.855B |
| Earnings Yield | -5.20% |